go back

Rhode Island rates for HCPCS Q2055

Idecabtagene vicleucel, up to 510 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Facilitymedian $562,341 · 10th–90th $562,341–$1,096,4780%50%90th$562,341Professionalmedian $562,341 · 10th–90th $562,341–$575,4400%50%90th$562,341$100.0K$200.0K$500.0K$1.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample — interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Facility/Professional
Facility
Modifier
Typical Low / Median / Typical High
$1,096,478.20 / $1,096,478.20 / $1,096,478.20
Aetna
Facility/Professional
Professional
Modifier
Typical Low / Median / Typical High
$562,341.33 / $575,439.94 / $575,439.94
BCBS
Facility/Professional
Facility
Modifier
Typical Low / Median / Typical High
$562,341.33 / $562,341.33 / $588,843.66
BCBS
Facility/Professional
Professional
Modifier
Typical Low / Median / Typical High
$562,341.33 / $562,341.33 / $562,341.33
United
Facility/Professional
Facility
Modifier
Typical Low / Median / Typical High
$562,341.33 / $562,341.33 / $562,341.33
United
Facility/Professional
Professional
Modifier
Typical Low / Median / Typical High
$60,255.96 / $60,255.96 / $60,255.96